John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$175M |
| 2 |
Meta Platforms (Facebook)
META
|
+$163M |
| 3 |
ABMD
Abiomed Inc
ABMD
|
+$138M |
| 4 |
Constellation Brands
STZ
|
+$135M |
| 5 |
Johnson & Johnson
JNJ
|
+$132M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$173M |
| 2 |
Pfizer
PFE
|
+$159M |
| 3 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$136M |
| 4 |
Dominion Energy
D
|
+$133M |
| 5 |
eBay
EBAY
|
+$118M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.76% |
| 2 | Consumer Discretionary | 11% |
| 3 | Industrials | 10.42% |
| 4 | Healthcare | 9.63% |
| 5 | Financials | 8.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
iShares Russell 1000 Growth ETF
IWF
$125B
| $22.2M | 0.07% |
618,400
+560,400
| +966% | +$19.8M |
|
|
INXN
377
DELISTED
Interxion Holding N.V.
INXN
| $22.2M | 0.07% |
354,864
-118,878
| -25% | -$7.6M |
|
378
PUT
Intel
INTC
$476B
| $22.1M | 0.07% |
445,400
+111,300
| +33% | +$5.91M |
|
379
Travel + Leisure Co
TNL
$4.39B
| $22.1M | 0.07% |
499,814
+113,099
| +29% | +$5.58M |
|
|
BPMC
380
DELISTED
Blueprint Medicines
BPMC
| $22.1M | 0.07% |
347,838
+272,350
| +361% | +$21.7M |
|
381
Canadian Natural Resources
CNQ
$106B
| $22.1M | 0.07% |
1,249,694
+1,213,295
| +3,333% | +$20.5M |
|
382
CALL
iShares Russell 2000 ETF
IWM
$81.9B
| $21.9M | 0.07% |
134,000
+53,800
| +67% | +$8.61M |
|
383
CALL
PepsiCo
PEP
$196B
| $21.9M | 0.07% |
200,900
+162,300
| +420% | +$16.8M |
|
384
Philips
PHG
$26.8B
| $21.8M | 0.07% |
664,563
+460,252
| +225% | +$14.7M |
|
385
Visteon
VC
$2.83B
| $21.8M | 0.06% |
168,377
+26,342
| +19% | +$3.29M |
|
386
iShares Select Dividend ETF
DVY
$23.9B
| $21.7M | 0.06% |
222,097
-125,465
| -36% | -$12.2M |
|
387
Danaher
DHR
$154B
| $21.7M | 0.06% |
247,770
+180,468
| +268% | +$16.1M |
|
388
PUT
American Tower
AMT
$81.9B
| $21.6M | 0.06% |
150,100
+111,100
| +285% | +$15.4M |
|
389
Essent Group
ESNT
$6.12B
| $21.3M | 0.06% |
595,710
+514,792
| +636% | +$18.6M |
|
390
CALL
Gilead Sciences
GILD
$181B
| $21.3M | 0.06% |
301,200
+221,600
| +278% | +$15.6M |
|
|
TMX
391
DELISTED
Terminix Global Holdings, Inc.
TMX
| $21.3M | 0.06% |
534,263
+279,545
| +110% | +$10.4M |
|
|
LSXMK
392
DELISTED
Liberty Media Corporation Series C Liberty SiriusXM Common Stock
LSXMK
| $21.2M | 0.06% |
614,201
-3,600
| -0.6% | -$120K |
|
|
ESRX
393
DELISTED
Express Scripts Holding Company
ESRX
| $21.2M | 0.06% |
274,294
+191,887
| +233% | +$14.4M |
|
394
International Flavors & Fragrances
IFF
$21.5B
| $21.2M | 0.06% |
170,646
+42,119
| +33% | +$5.5M |
|
395
National Grid
NGG
$80.2B
| $21.1M | 0.06% |
426,222
+297,106
| +230% | +$15M |
|
396
Bio-Rad Laboratories Class A
BIO
$10.2B
| $21M | 0.06% |
72,799
+26,159
| +56% | +$7.22M |
|
397
CALL
Chevron
CVX
$403B
| $20.9M | 0.06% |
165,700
+106,800
| +181% | +$13.3M |
|
398
Archer Daniels Midland
ADM
$38.7B
| $20.9M | 0.06% |
456,072
-763,931
| -63% | -$34.3M |
|
399
Nu Skin
NUS
$231M
| $20.8M | 0.06% |
266,423
-62,947
| -19% | -$4.88M |
|
400
Telus
TU
$15.6B
| $20.8M | 0.06% |
1,172,514
-44,772
| -4% | -$792K |
|
Similar funds
John Overdeck's Q2 2018 Portfolio in Review
As of Q2 2018, John Overdeck held 3,907 positions worth $33.5B, up 12% from $30B the previous quarter. Its ten largest holdings account for 5.6% of the portfolio.
John Overdeck deployed $2.27B of net new capital in Q2 2018, opening 829 new positions and adding to 1,295 existing holdings. Its largest new stake was Alphabet (Google) Class A: 3,215,020 shares worth $182M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Industrials.
On the sell side, the largest reduction was Booking.com, an estimated $173M trimmed.
- John Overdeck's largest Q2 2018 buy was Alphabet (Google) Class A: 3,215,020 shares worth $182M.
- John Overdeck added most to Abiomed Inc in Q2 2018, an estimated $138M increase.
- John Overdeck's biggest Q2 2018 reduction was Booking.com, cutting an estimated $173M.
- John Overdeck fully exited Pfizer in Q2 2018, selling an estimated $159M.
- John Overdeck's ten largest holdings make up 5.6% of its $33.5B portfolio in Q2 2018.
- John Overdeck opened 829 new positions and closed 662 in Q2 2018.
- John Overdeck's portfolio value rose 12% quarter-over-quarter to $33.5B.
Based on Two Sigma Investments's 13F filing for Q2 2018, filed 14 Aug 2018.